CDXC News and Press, ChromaDex Corporation

2025-06-10 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-04-22 16:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will change its corporate name to Niagen Bioscience, Inc. and trade under the new Nasdaq symbol “NAGE” effe...

ChromaDex Corp . (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announces that senior management will participate at the 37th Annual ROTH Conference . ChromaDex CEO, Rob Fried, will participate on ...

2025-03-06 10:30:33 ET Summary ChromaDex Corporation shows strong revenue growth and profitability, driven by its NAD+ precursors and flagship product Niagen, despite high valuation and execution risks. Record-breaking financial performance includes a 37.41% revenue increase, $7.2...

2025-03-04 20:53:47 ET ChromaDex Corporation (CDXC) Q4 2024 Earnings Conference Call March 04, 2025, 04:30 PM ET Company Participants Ben Shamsian - Vice President, Lytham Partners, Investor Relations Rob Fried - Chief Executive Officer Ozan Pamir - Chief Financi...

2025-03-04 16:05:29 ET More on ChromaDex Seeking Alpha’s Quant Rating on ChromaDex Historical earnings data for ChromaDex Financial information for ChromaDex Read the full article on Seeking Alpha For further details see: ChromaDex GAAP EPS...

Full year net sales of $99.6 million, up 19% from the prior year, gross margin of 61.8%, net income of $8.6 million, Adjusted EBITDA of $8.5 million, and $12.1 million in operating cash flows. Ended the year with $44.7 million in cash and no debt. Fourth quarter net sales of $29.1 million, up 37%...

Veritec, Inc. (VRTC) is expected to report for quarter end 2024-12-31 Nayax Ltd. (NYAX) is expected to report $0.04 for Q4 2024 CrowdStrike Holdings Inc. (CRWD) is expected to report $0.01 for Q4 2025 Schaeffler AG Bearer Preference Shares (SCFLF) is expected to report for quarter end...

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research with a focus on healthy aging, announces that it will hold a conference call on Tuesday, March 4, 2025, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fisc...